Merck and Eisai's Dual Regimen Receives the US FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Unresectable Hepatocellular Carcinoma
Shots:
- The BT designation is based on P-Ib KEYNOTE-524/Study 116 trial assessing Keytruda (200mg- IV- q3w) + Lenvima (12mg/day for patients weighing ≥60kg- and 8mg/day for patients weighing <60kg) in patients with unresectable HCC not amenable to locoregional treatment
- The FDA’s BT designation intended to expedite development and review of medicines for serious or life-threatening conditions
- This marks the third BT designation for the combination therapy. The first two BT designation for dual regimen was in advanced/m-RCC & advanced/ m-non- MSI-H/ pMMR endometrial carcinoma- received in Jan’2018 & July’2018 respectively
Click here to read full press release/ article
Ref: Merck | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com